Genprex
(NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique,
nonviral proprietary platform designed to deliver tumor suppressor genes to
cancer cells, today announced that the U.S Food and Drug Administration (FDA)
has granted Fast Track Designation for Genprex’s Oncoprex(TM) immunogene
therapy in combination with EGFR inhibitor osimertinib (AstraZeneca’s
Tagrisso(R)). Tagrisso(R), with worldwide sales of $1.86 billion in 2018 and
$2.31 billion in the first 9 months of 2019, is currently AstraZeneca’s highest
grossing product for the treatment of non-small cell lung cancer (NSCLC)
patients with EFGR mutations that progressed after treatment with osimertinib
alone. Genprex has treated more than 50 lung cancer patients with Oncoprex,
comprised of the TUSC2 (Tumor Suppressor Candidate 2) gene complexed with a
lipid nanoparticle, in Phase I and II clinical trials. “Genprex is excited to
receive this important FDA designation,” Genprex Chairman and Chief Executive
Officer Rodney Varner said in the news release. “In addition to potentially
facilitating and expediting our pathway to approval, we believe that this FDA
designation validates our plan to commercialize Oncoprex immunogene therapy in
combination with EGFR inhibitors for the treatment of lung cancer. We hope that
Fast Track Designation helps us bring our gene therapy to patients more rapidly
and that our unique gene therapy platform is more widely recognized for its
potential in cancer treatment.”
To view the full press release, visit http://ibn.fm/o1uUa
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for cancer patients based
upon a unique proprietary technology platform. Genprex’s platform technologies
are designed to administer cancer-fighting genes by encapsulating them into
nanoscale hollow spheres called nanovesicles, which are then administered
intravenously and taken up by tumor cells where they express proteins that are
missing or found in low quantities. The company’s lead product candidate,
Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), has a
multimodal mechanism of action whereby it interrupts cell signaling pathways
that cause replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells, and
modulates the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. For more information,
please visit the company’s web site at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
